Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib in HER2+ Metastatic Colorectal Cancer
NCT05253651Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Tucatinib Arm with Standard of Care Arm (2 arms). Primary endpoint: Progression-Free Survival per RECIST v1.1 by BICR at 3 years. Started Oct 2022; status: recruiting.
02
Drugs
tucatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05253651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253651.